A study assessing the EMPA‐REG CVOT inclusion criteria against the RCGP RSC cohort database reported that the inclusion criteria are applicable only to a small proportion of people with type 2 diabetes (15.7% of the total type 2 diabetes population), and that an even smaller proportion of those who are currently treated with SGLT2 inhibitors have the same high CV risk as that of the EMPA‐REG trial population (11.1% of the total type 2 diabetes population), thus calling into question whether this class of drug is also being used to its potential, at least in England.42 This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.